latanoprost/timolol (T2347) / Thea Laboratories - LARVOL DELTA

Establishment and characterization of a hormone dependent, PSA/PSMA positive prostate PDX model (EORTC-NCI-AACR 2016) - "ST1273 and CBX models reported variable activity towards docetaxel and the targeted therapies abiraterone and enzalutamide. Results were compared with the five cell-based xenograft (CBX) prostate models LNCaP, PC-3, DU145, EE06AA-hT and VCaP and a second prostate PDX designated (ST2347). We have established and characterized a PDX representing hormone-dependent, PSA/PSMA positive prostate cancer designated ST1273 and benchmarked it against standards of care and CBX prostate xenografts. We have also demonstrated its utility towards evaluating PSMA-targeting therapies"

Biosimilar • Oncology • Prostate Cancer

Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension. (PubMed, J Glaucoma) - "Preservative-free latanoprost-timolol fixed combination T2347 showed noninferior efficacy compared with the preserved comparator and was well tolerated."

Clinical • Head-to-Head • Journal • Glaucoma • Hypertension • Ophthalmology

Generic glaucoma medication costs: a 2 year analysis (ARVO 2016) - "The increase in cost of most generic medications significantly surpassed inflation. Cash paying patients and providers are encouraged to explore costs of different medications at various pharmacies in order to lower health care costs."

HEOR • Glaucoma • Ophthalmology

Efficacy of latanoprostene bunod 0.024%vs.timolol maleate 0.5% for intraocular pressure lowering in patients with open-angle glaucoma or ocular hypertension: the LUNAR Study (ARVO 2016) - P3, N=387; "Results from this randomized controlled trial demonstrate that LBN 0.024% instilled qPM was effective at reducing IOP in patients with OAG or OHT over a 3 month period with a favorable safety profile."

P3 data • Glaucoma • Ophthalmology

Characterizing concordance in timolol response by aqueous flow and IOP (AGS 2016) - P=NA, N=74; NCT01677507; "Variations in timolol response by IOP and aqueous flow are not affected by demographic variables, cornea biometrics, or blood pressure. Given the growing list of genes associated with IOP our next steps are to
determine the role of IOP-associated genes in these variations in timolol response by IOP and aqueous flow."

Biomarker • Glaucoma • Ophthalmology

Generic vs. branded drugs: Just how equal is equal? (American Academy of Ophthalmology) - "Then there's the matter of excipients, like preservatives, pH adjusters, antioxidants, thickening agents, buffers and substances to adjust tonicity. The excipients can mean the difference between a drug clumping or staying in solution, or causing more redness or less. 'There's a balancing act that manufacturers are doing when formulating ocular preparations,' Dr. Noecker said....On the other hand, prostaglandins, like latanoprost, are more challenging to formulate. 'Latanoprost is lipophilic. It doesn't like water. It doesn't go easily into solution,' Dr. Noecker said, adding that the developer worked hard to adjust the preservative so more of the drug went into solution."

Media quote

Non-inferiority of Preservative-free versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients with Open-angle Glaucoma or Ocular Hypertension. (PubMed, J Glaucoma) - "Preservative-free latanoprost-timolol fixed combination T2347 showed non-inferior efficacy compared to the preserved comparator and was well tolerated.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/- ."

Clinical • Head-to-Head • Journal